In today’s session GW Pharmaceuticals PLC- ADR (GWPH) registered an unusually high (1,040) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious GWPH increase. With 1,040 contracts traded and 10624 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: GWPH170120C00145000 closed last at: $13.2 or 48.3% up. About 527,323 shares traded hands. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has risen 247.33% since March 1, 2016 and is uptrending. It has outperformed by 238.09% the S&P500.
Analysts await GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to report earnings on December, 5. They expect $-1.59 earnings per share, down 87.06% or $0.74 from last year’s $-0.85 per share. After $-0.73 actual earnings per share reported by GW Pharmaceuticals PLC- ADR for the previous quarter, Wall Street now forecasts 117.81% negative EPS growth.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Ratings Coverage
Out of 7 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 5 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 71% are positive. $182 is the highest target while $129 is the lowest. The $150.20 average target is 12.93% above today’s ($133) stock price. GW Pharmaceuticals has been the topic of 9 analyst reports since August 13, 2015 according to StockzIntelligence Inc. TH Capital initiated it with “Buy” rating and $130 target price in Monday, November 30 report. The company was maintained on Monday, September 26 by Cantor Fitzgerald. The rating was initiated by Janney Capital on Monday, June 27 with “Sell”. The stock of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) earned “Buy” rating by Cantor Fitzgerald on Friday, June 3. On Friday, August 26 the stock rating was upgraded by Numis Securities to “Hold”. The firm has “Buy” rating given on Monday, November 30 by Roth Capital. The rating was initiated by Morgan Stanley on Thursday, August 13 with “Overweight”. Roth Capital maintained GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) on Monday, March 14 with “Buy” rating.
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The company has a market cap of $3.35 billion. The Firm develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. It currently has negative earnings. The Firm operates through three divisions: Commercial, Sativex Research and Development , and Pipeline Research and Development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.